HESKA CORPORATION

Investor Presentation

June 2021

Kevin Wilson Chief Executive Officer & President

01 FORWARD-LOOKING STATEMENT & SAFE HARBOR DISCLAIMER

This presentation contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as

defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would",

"will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to, among other things,

our future financial and operating results, future sales, sales split percentages, sales geography percentages, market share, and strategic goals, long-term financial model, revenue growth

potential, new product launch and performance, and the anticipated benefits of the scil acquisition and other acquisitions. These statements are intended to provide management's

expectation of future events as of the date of this webcast; are based on management's estimates, projections, beliefs and assumptions as of the date of this webcast; and are not guarantees

of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or

achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact,

and the duration, of the effects of the ongoing COVID-19 pandemic on consumer demand, our global supply chain and our business, results of operations, liquidity, financial condition and

stock price, the ability to achieve the anticipated benefits of the scil acquisition and other acquisitions; supplier availability, competing suppliers, any product’s ability to perform and be

recognized as anticipated, in particular when such product is under development; Heska’s ability to sell and market its products in an economically sustainable fashion, including related to

varying customs, cultures, languages and sales cycles and uncertainties with foreign political and economic climates; the Company’s ability to integrate the acquired scil business within its

existing operations; and new product development and release schedules, as well as the other matters described under the headings "Business," "Risk Factors," "Legal Proceedings,"

"Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report

on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q for the period ended March 31, 2021, as well as those described from time to time in the

Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking

statement, whether as a result of new information, future events or otherwise.

2

01

02

03

04

05

Heska Strategic Role in Global Veterinary Health Market

& Heska Strategic Plan

Double Customers & Geography Served

Double Product & Revenue Streams Served

Key Metrics & Considerations

Question & Answer

HESKA INVESTOR PRESENTATION

Heska Strategic Role in Global Veterinary Health Market

& Heska Strategic Plan

01

5

Veterinary Healthcare01

• Humanization of pets globally. “Pet families”

• Adoption rates at historic levels

• 10-14 year juvenile, wellness and aging care

• Greater awareness of pet health and pet symptoms

• Historically recession resistant

• Positive regulatory, payor and demographic trends

• Accelerating industry investment and consolidation

Point of Care Diagnostics

• ~8%-10% Annual Global Veterinary Diagnostics Growth1

• Major veterinarian revenue / profit center in hospitals

• Diagnostics utilization is key

• Increases in hospital pet visits and POC utilization

• Favored by veterinarians (veterinary licensure required)

• New technologies and advancements pull tests to point of care

• Pricing tends to increase each year

• High priority spend; often first spend in tight budgets

Annual growth rate information derived from publicly available information data disclosed by third-party sources, our own internal estimates based on such data, and our knowledge of the industry; it has not been independently verified. Source: American Pet Prod Assoc Generational Report; 2017-18 Pet Owners’ Survey; American Pet Products Association1 Technavio Global Veterinary Diagnostics Market 2017-2021 report.

6

Supportive Growth Trends Global & Demographic01

Average Canine Vet Visits per Year by GenerationAverage Canine Vet Visits per Year by GenerationAverage Canine Vet Visits per Year by GenerationAverage Canine Vet Visits per Year by Generation

2.6 2.6 2.6

3.3

Silent Generation Baby Boomers Gen X Millennials

Global Veterinary Diagnostics Market > $2 BillionGlobal Veterinary Diagnostics Market > $2 BillionGlobal Veterinary Diagnostics Market > $2 BillionGlobal Veterinary Diagnostics Market > $2 Billion

Amounts estimated. Source: AVMA Report on the Market for Veterinary Services; American Pet Prod Assoc Generational Report; 2017-18 Pet Owners’ Survey; American Pet Products Association; Technavio Global Veterinary Diagnostics Market 2017-2021 report; 1 Represents increase in pet visits per year across generations

1,813 1,976

2,154

2,352

2,574

2017 2018 2019 2020 2021

7

01

Diagnostics Drives “Test & Treat”Diagnostics Drives >25% of Care

Diagnostics Drives Rx & Therapy

(1) POC Blood-Plasma (2) POC Urine-Fecal(3) POC Imaging (4) Telemed & Data(5) Single Use Rapids (6) Central Ref Lab

8

A 15 Year Campaign in Three Acts.01

Act Two 2018 through 2023

Build Intrinsic ValueBuild Revenue Growth

Act One 2013 through 2017

Prove HealthyProve Relevance

Act Three 2024 through 2027

Win at ScaleWin at Reinvention

9

Successful Act One (2013-2017)01

Getting Product

Right

Getting TeamRight

GettingCostsRight

Getting ModelRight

Getting

NarrativeRight

¹ 2017 U.S Tax Reform impacts of +/- ($5.9M) included, as further discussed in our Form 10-K/A for the year ended December 31,2017

$MM, except p/shareHeskaHeskaHeskaHeska

2013201320132013

HeskaHeskaHeskaHeska

2017201720172017

RevenueRevenueRevenueRevenue $78.3 $129.3

Gross Margin %Gross Margin %Gross Margin %Gross Margin % 39% 45%

Operating Margin %Operating Margin %Operating Margin %Operating Margin % (2%) 14%

Operating IncomeOperating IncomeOperating IncomeOperating Income ($1.43) $18.2

EarningsEarningsEarningsEarnings Per SharePer SharePer SharePer Share ($0.21) $1.3¹

AssetsAssetsAssetsAssets $93.6 $135.8

EquityEquityEquityEquity $47.1 $100.4

10

Heska End State Goal for Act Two 2018 - 202301

1. Growth. Growth. Growth. Sales & Margin Mix.

2. Top the innovation and value creation chain.

3. “Closest to the Veterinarian” for decades.

4. #1 or #2 in “Must Have” geographies.

5. Strong and enlarged balance sheet. Strong pipeline.

11

Heska Three Point Strategy for Act Two 2018 - 202301

Double Customers & Geography Served

Double Product & Revenue Streams Served

Continue Core Base Business Growth

Double Customers & Geography Served02

13

Double Customers and Geography. 25 Markets… and Growing.02

United States

Canada

Australia

Latin America

Germany Spain

Canada France

Italy Netherlands

Czech Republic Poland

United Kingdom Scandinavia

Malaysia and More

Spain France

14

“Closest to Veterinarians” Leadership in Core Markets02

Over 500 Professionals with over 150 Direct Sales

Direct Sales Teams in 10 Countries

Direct Logistics and Operations in 7 Countries

Over 30,000 Analyzers Installed

Over 6,000 Imaging Devices Installed (DX/CR/US)

North America #3 ≈ 13%

Germany #1 ≈ 40%

Spain #1 ≈ 40%

France #2 ≈ 30%

Italy #2 ≈ 30%

Percentages and rankings are internal estimates for automated (1) POC Blood Lab, (2) Imaging, or (3) POC Blood Lab & Imaging. Excludes reference lab, single use testing, production animal testing, manual testing and all other diagnostics which, together, represent >50% of the addressable market in animal health diagnostics.

14

15

New Global Presence to Double Customer Opportunities02

2018 Sales Geography

RoW 2%Canada 2%

Europe 5%

USA91%

North America~66%

PanEurope~32%

RoW ~2%

2020 Sales Geography

Global #2 in POC Lab-Imaging Diagnostics (1)

1. All amounts rounded and not GAAP. Refer to 10-K ending December 31, 2018 and 2020 for GAAP, segments, revenue recognition, and other information relevant. Global market place estimated by management for point of care blood-plasma and imaging diagnostics customers and revenues.

16

Consolidated Sales Mix Moved to Focus on POC Diagnostics02

2018 Sales Mix(1)

15%POC Lab

45%

POC Imaging18%

Other Vaccine & Pharma

Other Core Comp. Animal

22%

2020 Sales Mix(2)

~8%

POC Lab~58%

POC Imaging~22%

~12%

Other Vaccine & Pharma

Other Core Comp. Animal

2. All amounts rounded and not GAAP. Refer to 10-K ending December 31, 2020 for GAAP, segments, revenue recognition, and other information relevant to (1) and (2). Management believes this visual will assist investors to understand the Company’s business and strategy.

1. All amounts rounded and not GAAP. Refer to 10K ending December 31, 2018 for GAAP, segments, revenue recognition, and other information relevant to (1) and (2).

Double Product & Revenue Streams Served03

18

Research and Development Investments03

1. New Analyzer and Diagnostics Platforms

2. Menu expansion to all Analyzer Platforms

3. Upgrade cycle to currently installed Analyzer Platforms

4. Heska in-house Inventions to Early Mover Lines

19

Business Development Investments03

1. Go Faster & Deeper in New Platforms, Menu, Services

2. Go Faster & Deeper in New Markets & Geography

3. Attention to Strategic and Accretive Value

20

Leading Point of Care Full Portfolio “Complete Voice of the Pet”03

Element HT5

Hematology

Element COAG+™

Coagulation

Element DC

Chemistry

Portable Digital

Radiography

Element RC3X

Rotor Chemistry

Hospital Digital

Radiography

Element DC5X

Dry Chemistry

Element RCX

Rotor Chemistry

Digital

Endoscopy

HeskaView

Connect™

HeskaView

Cloud™

HeskaView

Telecytology™

Digital

Ultrasound

Element i+®

Immunoassay

Element POC

Gas & E-M Lyte

Allergy Diagnostic

Immunotherapy

Element AIM

Urine, Fecal &

Microscopy

21

Heska Global Imaging Diagnostics Upgrade Cycle 2H 202103

1. Global upgrade cycle within our installed base of over 6,000 sites

2. New Products to hit new price points to open new markets

22

Expanding Rotor Chemistry International Family 1H 202103

Statements related to rotor chemistry are forward looking statements about development activities

that are uncertain and cannot be guaranteed to succeed, launch, or provide benefit.

23

Immunodiagnostics Multi Plex Analyzer 1H 202103

2021 Assays in DevelopmentNon-Regulatory (USDA)

Total T4

Cortisol

TSH

Progesterone

2021 Assays in DevelopmentRegulated (USDA)

Canine Heartworm (4+ Plex)

Lyme (4+ Plex)

Anaplasma (4+ Plex)

Ehrlichia (4+ Plex)

24

Handheld COAG Analyzer 1H 202103

Statements are forward-looking statements about development activities that are uncertain and cannot

be guaranteed to succeed, launch, or provide benefit.

• Upgraded Handheld COAG PT/aPTT combo test

• Untreated whole blood direct or standard citrated

sample after recalcification

• Dry-reagent strips stored at room temperature

• Small blood sample volume

• Fast results

• Stable external quality controls

• Upgrade of current installed base

25

Urine – Fecal – Cytology AI Microscopy Solution03

Key Design Philosophy

Urine & Fecal Testing

Cytology*

Artificial Intelligence (Heska Neural Network)

*Element AIM is a product in development. All statements about Element AIM are forward looking statements about development activities that are uncertain and cannot be guaranteed to succeed, launch, or provide benefit.

Built for Veterinarians to AI automate millions of in-clinic procedures currently done at point of care.

26

03

Element AIM Manufacturing in New England, USA

Limited Early Adopter Installations targeted for Q2 2021

Limited Pre-Order & Key Account Installs targeted for Q3 2021

General Release Pre-Order Installations targeted for Q4 2021

General Release targeted for Q1 2022

International Markets targeted for One Quarter Later

*Element AIM is a product in development. All statements about Element AIM are forward looking statements about development activities that are uncertain and cannot be guaranteed to succeed, launch, or provide benefit.

Urine – Fecal – Cytology* Artificial Intelligence Microscopy Solution

27

Heska Launches Cloud-Based Professional Services Platform in 202103

HeskaView Telecytology™: Digital Cytology Services

Acquired Lacuna Diagnostics in Q1 2021 (small install base)

Over 25 Boarded Pathologists

Scale with Heska Sales & Field Teams in North America & International

Heska Point of Care Lab Subscribers (> 6,000 estimated to be eligible)

Heskaview Cloud™: Archive-Report-View-Share-Artificial Intelligence

03

*Products and services in development. All statements are uncertain as to forward looking performance and cannot be guaranteed to succeed, launch, or provide benefits noted.

31

29

New Cloud Based Data Solution Ties it all Together03

Overview & Summary

1. Archive, Share, Report on mobile and desktop environments

2. Multi-modality radiology and microscopy imaging

3. Lab reporting integration into unified cloud patient records

4. Part of Heska’s leading PIMS integrations across the world

5. Scalable cloud and data infrastructure for the next decade

6. Full telemedicine support. DICOM.

Key Metrics & Considerations04040404

31

~90%+ of Heska POC Lab Consumables on Long-Term Subscription (1), (2), (3)04

1. Includes 2020 Corporate Accounts estimates similar to individual accounts CSV (“Contract Subscription

Value”). 2. As of December 31, 2020. Refer to Company’s Fourth Quarter and Full Year Financial Results in

the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 . 3. Represents

minimum contract subscription value / subscription months 4. Represents the percentage of subscribers

that renew their contracts

Subscriber Retention >95%4

Minimum contract subscription value ($MM)3

+34%+34%+34%+34%

+11%+11%+11%+11%

+28%+28%+28%+28%

2013201320132013 2014201420142014 2015201520152015 2016201620162016 2017201720172017 2018201820182018 2019201920192019 2020202020202020

SubscriptionsSubscriptionsSubscriptionsSubscriptions 370 730 1,239 1,667 1,950 2,175 2,376 2,980

% Growth -- 97% 69% 35% 17% 12% 9% 25%

Months Under SubscriptionMonths Under SubscriptionMonths Under SubscriptionMonths Under Subscription -- -- 54,200 68,750 75,950 90,850 100,249 124,695

% Growth -- -- -- 27% 10% 20% 10% 24%

Minimum Contract Subscription ValueMinimum Contract Subscription ValueMinimum Contract Subscription ValueMinimum Contract Subscription Value -- -- $38.0 $51.0 $56.4 $71.9 $101.6 $131.4

% Growth -- -- -- 34% 11% 28% 41% 29%

+41%+41%+41%+41%

$38.0

$51.0

$56.4

$72.0

$101.6

$131.4

+29%+29%+29%+29%

Favorable Liquidity Position04040404

32

• Successfully raised over $375 million over last 24 months

• Funded over $125 million in strategic acquisitions in 2020

• Continued investment in new product offerings

• Remain active in M&A market

04040404

Multi-Year Outlook04040404

33

(1) Equal to or greater than the number noted. Non-GAAP - Excludes estimates for taxes, interest, depreciation and amortization, acquisition and other one-time costs, and stock-based compensation.

Note: Heska is unable to provide a reconciliation of the Non-GAAP guidance measure to the corresponding GAAP measure on a forward-looking basis without unreasonable effort due to the high variability and low visibility of most of the

excluded items. Material changes to any one of these items could have a significant impact on future GAAP results. These financial estimates are forward looking statements subject to numerous factors outlined in the Safe Harbor in this

presentation and actual results may materially differ.

• Transitioned commercial programs to subscriptions

• Global reach with new products

• Continued mix shift to diagnostics

• Leveraged operating costs

Increased profitability over time:

2021202120212021 2022202220222022 2023202320232023

Revenue Revenue Revenue Revenue (Millions) $225-$235 $250-260 $275-285

POC Lab Revenue $135-$145

POC Imaging Revenue $50-$60

Gross Margin %Gross Margin %Gross Margin %Gross Margin % 39%-41% 41%-43% 44%-46%

Adjusted EBITDA MarginAdjusted EBITDA MarginAdjusted EBITDA MarginAdjusted EBITDA Margin(1)(1)(1)(1) 8% 12% 15%

Dollars in Millions

04040404

First Quarter 2021 Highlights

Key Metrics

• Revenue up 97.4% to $60.5MM

• North America POC Lab

Consumables Sales Up 23.9%

• Consolidated Gross Margin: 42.1%

Commentary

• Record quarterly revenue growth led by strong utilization, price, and mix in POC Lab

Consumables, Imaging and International markets.

• North America POC Lab Consumables sales up 23.9%; ahead of 2021 Outlook (>10%).

• North America: sales up 34.8%, gross margin 47%, up 176 bps compared to prior year.

• International: sales and gross margin continued to progress in line with stated goals.

• Key projects advanced within garget for 2021 commercial launches, including Element

AIM™, Element RCX, Element RC3X Element i+®, Element COAG+™, Heskaview Specialty

Services™ in digital cytology, Heskaview Cloud™, Heskaview Connect™, and others.

34Refer to Company’s First Quarter 2021 Financial Results in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2021.

04

QUESTION & ANSWER05050505